
Raymond R Townsend

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3935443/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA - Journal of the American Medical Association, 2014, 311, 507.	3.8	6,625
2	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	13.9	1,848
3	Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. Hypertension, 2015, 66, 698-722.	1.3	1,073
4	Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension, 2019, 73, e35-e66.	1.3	740
5	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	6.3	597
6	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	6.3	597
7	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis, 2015, 241, 507-532.	0.4	587
8	The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. Journal of the American Society of Nephrology: JASN, 2003, 14, S148-S153.	3.0	545
9	Large-Artery Stiffness in Health andÂDisease. Journal of the American College of Cardiology, 2019, 74, 1237-1263.	1.2	512
10	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Hypertension, 2014, 32, 3-15.	0.3	498
11	Chronic Renal Insufficiency Cohort (CRIC) Study. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1302-1311.	2.2	497
12	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
13	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	1.0	458
14	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQqO 1444-1451.	0 0 rgBT / 6.3	Overlock 10 Tf 351
15	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
16	Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2010, 55, 441-451.	2.1	320
17	Catheterâ€Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTNâ€ 3 Trial. Clinical Cardiology, 2012, 35, 528-535.	0.7	278
18	Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 371-380.	1.6	251

#	Article	IF	CITATIONS
19	Vascular Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 184-192.	2.2	218
20	Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2012, 60, 250-261.	2.1	207
21	Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary Study. American Journal of Hypertension, 2010, 23, 282-289.	1.0	192
22	Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. European Heart Journal, 2017, 38, 2805-2812.	1.0	175
23	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. Journal of the American College of Cardiology, 2014, 64, 1071-1078.	1.2	164
24	Masked Hypertension and Elevated Nighttime Blood Pressure in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 642-652.	2.2	157
25	Role of Ambulatory and Home Blood Pressure Monitoring in Clinical Practice. Annals of Internal Medicine, 2015, 163, 691-700.	2.0	144
26	Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. Annals of Internal Medicine, 2020, 173, 426-435.	2.0	144
27	Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure. Hypertension, 2017, 69, 42-50.	1.3	143
28	Race, Genetic Ancestry, and Estimating Kidney Function in CKD. New England Journal of Medicine, 2021, 385, 1750-1760.	13.9	142
29	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease. Hypertension, 2016, 67, 387-396.	1.3	134
30	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. American Heart Journal, 2016, 171, 82-91.	1.2	132
31	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. Annals of Internal Medicine, 2015, 162, 258-265.	2.0	128
32	Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis. Hypertension, 2015, 65, 93-100.	1.3	122
33	Blood Pressure Assessment in AdultsÂinÂClinicalÂPractice and Clinic-Based Research. Journal of the American College of Cardiology, 2019, 73, 317-335.	1.2	114
34	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQqO	0 0 rgBT /(Overlock 10 T
35	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. Journal of the American College of Cardiology, 2015, 65, 1314-1321.	1.2	103

³⁶Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality.1.31.3

#	Article	IF	CITATIONS
37	Cardioâ€ankle vascular index and cardiovascular disease: Systematic review and metaâ€analysis of prospective and crossâ€sectional studies. Journal of Clinical Hypertension, 2019, 21, 16-24.	1.0	95
38	A New Algorithm for the Diagnosis of Hypertension inÂCanada. Canadian Journal of Cardiology, 2015, 31, 620-630.	0.8	88
39	Chronic Renal Insufficiency Cohort Study (CRIC). Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2073-2083.	2.2	87
40	Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort Study. Circulation: Heart Failure, 2014, 7, 709-716.	1.6	84
41	SGLT2 inhibitors: their potential reduction in blood pressure. Journal of the American Society of Hypertension, 2015, 9, 48-53.	2.3	82
42	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society ofÂHypertension. Journal of the American Society of Hypertension, 2017, 11, 783-800.	2.3	81
43	Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovascular Diabetology, 2017, 16, 29.	2.7	80
44	Reflection Magnitude as a Predictor of Mortality. Hypertension, 2014, 64, 958-964.	1.3	79
45	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease. Annals of Internal Medicine, 2017, 167, 375.	2.0	78
46	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic) Tj ETQq0 0 0 r	gBT /Overlc 1.3	ock 10 Tf 50 38
47	Resistive and Pulsatile Arterial Load as Predictors of Left Ventricular Mass and Geometry. Hypertension, 2015, 65, 85-92.	1.3	75
48	Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 877-886.	3.0	71
49	Proteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease. Stroke, 2015, 46, 2075-2080.	1.0	70
50	Non-GFR Determinants of Low-Molecular-Weight Serum ProteinÂFiltration Markers in CKD. American Journal of Kidney Diseases, 2016, 68, 892-900.	2.1	70
51	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. European Heart Journal, 2019, 40, 743-751.	1.0	70
52	A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. American Journal of Hypertension, 2004, 17, 1056-1058.	1.0	69
53	Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. Journal of the American Society of Hypertension, 2016, 10, 224-234.e17.	2.3	68
54	Hypertension in Cancer Patients andÂSurvivors. JACC: CardioOncology, 2019, 1, 238-251.	1.7	68

#	Article	IF	CITATIONS
55	Arterial Stiffness: Recommendations and Standardization. Pulse, 2016, 4, 3-7.	0.9	67
56	Combination of Converting Enzyme Inhibitor With Diuretic for the Treatment of Hypertension. Archives of Internal Medicine, 1990, 150, 1175.	4.3	66
57	Arterial Stiffness in CKD: A Review. American Journal of Kidney Diseases, 2019, 73, 240-247.	2.1	65
58	Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney. Journal of the American Society of Nephrology: JASN, 2021, 32, 614-627.	3.0	64
59	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	1.2	63
60	Renal Denervation for TreatingÂHypertension. JACC: Cardiovascular Interventions, 2019, 12, 1095-1105.	1.1	61
61	lyengar Yoga versus Enhanced Usual Care on Blood Pressure in Patients with Prehypertension to Stage I Hypertension: a Randomized Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	0.5	59
62	Management of hypertension in chronic kidney disease. Nature Reviews Nephrology, 2015, 11, 555-563.	4.1	59
63	Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention, 2020, 16, 89-96.	1.4	59
64	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2019, 73, 806-814.	2.1	58
65	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. Hypertension, 2020, 75, 660-667.	1.3	57
66	Arterial stiffness and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 47-53.	1.0	56
67	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. Journal of the American Society of Hypertension, 2016, 10, 847-856.	2.3	56
68	Salt intake and insulin sensitivity in healthy human volunteers. Clinical Science, 2007, 113, 141-148.	1.8	55
69	Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. Journal of the American Society of Hypertension, 2012, 6, 309-315.	2.3	55
70	Circulating Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Kidney Dysfunction and Arterial Stiffness. American Journal of Hypertension, 2018, 31, 988-994.	1.0	55
71	Medical students and measuring blood pressure: Results from the American Medical Association Blood Pressure Check Challenge. Journal of Clinical Hypertension, 2017, 19, 614-619.	1.0	54
72	Systemic hemodynamic atherothrombotic syndrome (SHATS) – Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. Progress in Cardiovascular Diseases, 2020, 63, 22-32.	1.6	54

#	Article	IF	CITATIONS
73	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. American Journal of Kidney Diseases, 2017, 70, 844-858.	2.1	53
74	Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. Circulation Research, 2017, 120, 1151-1161.	2.0	52
75	Fixedâ€dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. Journal of Clinical Hypertension, 2019, 21, 4-15.	1.0	51
76	Mobile Health (mHealth) Technology: Assessment of Availability, Acceptability, and Use in CKD. American Journal of Kidney Diseases, 2021, 77, 941-950.e1.	2.1	49
77	Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2612-2619.	2.2	48
78	Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 559-569.	3.0	47
79	Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis. Hypertension, 2017, 70, 435-443.	1.3	47
80	Inflammation and Arterial Stiffness in Chronic Kidney Disease: Findings From the CRIC Study. American Journal of Hypertension, 2017, 30, 400-408.	1.0	46
81	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29013-29024.	3.3	46
82	Detection, evaluation, and treatment of severe and resistant hypertension. Journal of the American Society of Hypertension, 2014, 8, 743-757.	2.3	45
83	Late Systolic Central Hypertension as a Predictor of Incident Heart Failure: The Multiâ€Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2015, 4, e001335.	1.6	44
84	Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1971-1978.	1.1	44
85	History and Justification of a National Blood Pressure Measurement Validated Device Listing. Hypertension, 2019, 73, 258-264.	1.3	43
86	Central Pulse Pressure in Chronic Kidney Disease. Hypertension, 2010, 56, 518-524.	1.3	42
87	Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2015, 66, 266-273.	2.1	42
88	Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 2859-2869.	3.0	42
89	Effects of aerobic exercise on vascular function in nondialysis chronic kidney disease: a randomized controlled trial. American Journal of Physiology - Renal Physiology, 2019, 316, F898-F905.	1.3	42
90	Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. European Heart Journal, 2014, 35, 2115-2122.	1.0	41

#	Article	IF	CITATIONS
91	Clinical Use of Pulse Wave Analysis: Proceedings From a Symposium Sponsored by North American Artery. Journal of Clinical Hypertension, 2015, 17, 503-513.	1.0	41
92	Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1145-1151.	0.4	41
93	Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1507-1515.	2.9	40
94	Change in Measured GFR Versus eGFR and CKD Outcomes. Journal of the American Society of Nephrology: JASN, 2016, 27, 2196-2204.	3.0	38
95	Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2403-2410.	2.2	37
96	Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrology, 2019, 20, 60.	0.8	37
97	Renal denervation therapy for hypertension: pathways for moving development forward. Journal of the American Society of Hypertension, 2015, 9, 341-350.	2.3	36
98	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension, 2015, 9, 769-779.	2.3	36
99	Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	1.6	36
100	Twenty-Four–Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 2018, 138, 1602-1604.	1.6	36
101	Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. BMC Nephrology, 2018, 19, 150.	0.8	35
102	Cardiopulmonary exercise testing reveals subclinical abnormalities in chronic kidney disease. European Journal of Preventive Cardiology, 2018, 25, 1717-1724.	0.8	34
103	Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 2609-2621.	3.0	33
104	Confounding Factors in Renal Denervation Trials. Hypertension, 2020, 76, 1410-1417.	1.3	33
105	Serum Aldosterone and Death, End-Stage Renal Disease, and Cardiovascular Events in Blacks and Whites. Hypertension, 2014, 64, 103-110.	1.3	30
106	Sex Differences in the Incidence of Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S86-93.	0.9	30
107	The effects of angiotensin-II on lipolysis in humans. Metabolism: Clinical and Experimental, 2001, 50, 468-472.	1.5	29
108	Metabolic Syndrome, Components, and Cardiovascular Disease Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Nephrology, 2011, 33, 477-484.	1.4	29

#	Article	IF	CITATIONS
109	Muscarinic blockade inhibits gastric emptying of mixed-nutrient meal: effects of weight and gender. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R707-R714.	0.9	28
110	Management of Chronic Kidney Disease in an Academic Primary Care Clinic. American Journal of Nephrology, 2003, 23, 47-54.	1.4	28
111	MicroRNA biomarkers in clinical renal disease: from diabetic nephropathy renal transplantation and beyond. Food and Chemical Toxicology, 2016, 98, 73-88.	1.8	28
112	Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease. JAMA Ophthalmology, 2019, 137, 767.	1.4	28
113	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. Clinical Research in Cardiology. 2020. 109. 289-302.	1.5	28
114	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
115	Vascular Stiffness in Children With Chronic Kidney Disease. Hypertension, 2017, 69, 863-869.	1.3	27
116	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Journal of the American College of Cardiology, 2021, 78, 1028-1038.	1.2	27
117	American Society of Hypertension position paper: central blood pressure waveforms in health and disease. Journal of the American Society of Hypertension, 2016, 10, 22-33.	2.3	26
118	Retinopathy and Progression of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1217-1224.	2.2	25
119	Peripheral Determinants of Oxygen Utilization in HeartÂFailure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2020, 5, 211-225.	1.9	25
120	Ankle Brachial Index and Subsequent Cardiovascular Disease Risk in Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2016, 5, .	1.6	24
121	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American Journal of Kidney Diseases, 2019, 73, 437-458.	2.1	24
122	Central Blood Pressure and Chronic Kidney Disease Progression. International Journal of Nephrology, 2011, 2011, 1-7.	0.7	23
123	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. European Journal of Cancer, 2016, 53, 96-104.	1.3	23
124	Rationale and design of the Transformative Research in Diabetic NephropathyÂ(TRIDENT) Study. Kidney International, 2020, 97, 10-13.	2.6	23
125	Comparison of an in-pharmacy automated blood pressure kiosk toÂdaytime ambulatory blood pressure in hypertensive subjects. Journal of the American Society of Hypertension, 2015, 9, 123-129.	2.3	22
126	Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney International, 2016, 90, 1348-1356.	2.6	22

#	Article	IF	CITATIONS
127	Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 75, 394-403.	2.1	22
128	Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. American Journal of Kidney Diseases, 2021, 77, 44-55.	2.1	22
129	Analyzing the radial pulse waveform: narrowing the gap between blood pressure and outcomes. Current Opinion in Nephrology and Hypertension, 2007, 16, 261-266.	1.0	21
130	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp> . Catheterization and Cardiovascular Interventions, 2021, 98, 416-426.	0.7	21
131	Sleep duration and 24â€hour ambulatory blood pressure in adults not on antihypertensive medications. Journal of Clinical Hypertension, 2018, 20, 1712-1720.	1.0	20
132	The Role of the Renin-Angiotensin System in Insulin Sensitivity in Normotensive Subjects. American Journal of the Medical Sciences, 1993, 305, 67-71.	0.4	18
133	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. Hypertension, 2019, 74, 244-249.	1.3	17
134	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 1836-1846.	3.0	17
135	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. Clinical Research in Cardiology, 2021, 110, 725-731.	1.5	17
136	The Role of Glomerular Epithelial Injury in Kidney Function Decline in Patients With Diabetic Kidney Disease in the TRIDENT Cohort. Kidney International Reports, 2021, 6, 1066-1080.	0.4	17
137	Pathogenesis of Drug-Resistant Hypertension. Seminars in Nephrology, 2014, 34, 506-513.	0.6	16
138	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. Journal of Clinical Hypertension, 2015, 17, 743-750.	1.0	16
139	Carotid Artery Wall Thickness in Obese and Nonobese Adults With Obstructive Sleep Apnea Before and Following Positive Airway Pressure Treatment. Sleep, 2017, 40, .	0.6	16
140	Catheter-Based Renal Denervation for Hypertension. Current Hypertension Reports, 2018, 20, 93.	1.5	16
141	The Accuracy in Measurement of Blood Pressure (AIMâ€BP) collaborative: Background and rationale. Journal of Clinical Hypertension, 2019, 21, 1780-1783.	1.0	16
142	Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD. Journal of the American Society of Nephrology: JASN, 2020, 31, 2912-2923.	3.0	16
143	Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease (from the) Tj ETQq1	1 8.78431	.4 rgBT /Ovei
144	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. American Journal of Cardiology, 2016, 118, 1855-1860.	0.7	15

#	Article	IF	CITATIONS
145	Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. American Journal of Hypertension, 2020, 33, 1003-1010.	1.0	15
146	Arterial Stiffness, Kidney Function, and Chronic Kidney Disease Progression. Pulse, 2013, 1, 123-130.	0.9	14
147	Beyond Blood Pressure: Percutaneous Renal Denervation for the Management of Sympathetic Hyperactivity and Associated Disease States. Journal of the American Heart Association, 2015, 4, e001415.	1.6	14
148	Blood Pressure Effects of Yoga, Alone or in Combination With Lifestyle Measures: Results of the Lifestyle Modification and Blood Pressure Study (<scp>LIMBS</scp>). Journal of Clinical Hypertension, 2016, 18, 809-816.	1.0	13
149	Out-of-Office Blood Pressure Monitoring: A Comparison of Ambulatory Blood Pressure Monitoring and Home (Self) Monitoring Of Blood Pressure. Hypertension, 2020, 76, 1667-1673.	1.3	13
150	Association of 24-Hour Ambulatory Blood Pressure Patterns with Cognitive Function and Physical Functioning in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 455-464.	2.2	13
151	Orthostatic Hypertension and Intensive Blood Pressure Control; Post-Hoc Analyses of SPRINT. Hypertension, 2021, 77, 49-58.	1.3	13
152	Yoga and Hypertension. Journal of Clinical Hypertension, 2007, 9, 800-801.	1.0	12
153	Stroke in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S11-S16.	2.2	12
154	Resistant Hypertension. Hypertension, 2016, 68, 1073-1080.	1.3	12
155	Home Blood Pressure Monitoring in CKD. American Journal of Kidney Diseases, 2014, 63, 835-842.	2.1	11
156	Should living kidney donors with hypertension be considered for organ donation?. Current Opinion in Nephrology and Hypertension, 2015, 24, 594-601.	1.0	11
157	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. American Journal of Kidney Diseases, 2019, 74, 771-781.	2.1	11
158	Orthostatic Hypertension and Hypotension and Outcomes in CKD: The CRIC (Chronic Renal) Tj ETQq0 0 0 rgBT /	Overlock I 1.0	10
159	Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in Nonobese and Obese Adults. Hypertension, 2021, 77, 980-992.	1.3	11
160	Renal Denervation: A Review. American Journal of Kidney Diseases, 2022, 80, 527-535.	2.1	11
161	Increasing Use of Vitamin D Supplementation in the Chronic Renal Insufficiency Cohort Study. , 2014, 24, 186-193.		10

```
162Reducing Arterial Stiffness in CKD. Clinical Journal of the American Society of Nephrology: CJASN,<br/>2015, 10, 547-550.2.210
```

#	Article	IF	CITATIONS
163	A study of the VaSera arterial stiffness device in <scp>US</scp> patients. Journal of Clinical Hypertension, 2017, 19, 661-668.	1.0	10
164	Effect of CPAP, Weight Loss, or CPAP Plus Weight Loss on Central Hemodynamics and Arterial Stiffness. Hypertension, 2017, 70, 1283-1290.	1.3	10
165	The Feasibility and Safety of Obtaining Research Kidney Biopsy Cores in Patients with Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1024-1026.	2.2	10
166	Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis. Journal of Cardiac Failure, 2022, 28, 540-550.	0.7	10
167	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. Hypertension, 2022, 79, 1506-1514.	1.3	10
168	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. Clinical Cardiology, 2015, 38, 447-454.	0.7	9
169	Ambulatory Arterial Stiffness Index and circadian blood pressure variability. Journal of the American Society of Hypertension, 2015, 9, 705-710.	2.3	9
170	<scp>Blood Pressure</scp> in Patients With Atrial Fibrillation: Part 1––Measurement. Journal of Clinical Hypertension, 2017, 19, 98-99.	1.0	9
171	Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial. American Journal of Kidney Diseases, 2021, 77, 12-22.	2.1	9
172	A randomized trial of aerobic exercise in chronic kidney disease: Evidence for blunted cardiopulmonary adaptations. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101469.	1.1	9
173	Vitamin K status, all-cause mortality, and cardiovascular disease in adults with chronic kidney disease: the Chronic Renal Insufficiency Cohort. American Journal of Clinical Nutrition, 2022, 115, 941-948.	2.2	9
174	Cardiovascular Implications of the 2021 KDIGO Blood Pressure Guideline for Adults With Chronic Kidney Disease. Journal of the American College of Cardiology, 2022, 79, 1675-1686.	1.2	9
175	Central Blood Pressure and Pulse Wave Velocity Changes Post Renal Denervation in Patients With Stages 3 and 4 Chronic Kidney Disease: The Regina RDN Study. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811982838.	0.6	8
176	Can we justify goal blood pressure of <140/90 mm hg in most hypertensives?. Current Hypertension Reports, 2005, 7, 257-264.	1.5	7
177	Of Funnel Arms, Popeye, and Other‣ized Challenges. Journal of Clinical Hypertension, 2005, 7, 755-756.	1.0	7
178	Top 10 landmark studies in hypertension. Journal of the American Society of Hypertension, 2014, 8, 437-447.	2.3	7
179	Which Patients Does the <scp>SPRINT</scp> Study <i>Not</i> Apply To and What Are the Appropriate Blood Pressure Goals in These Populations?. Journal of Clinical Hypertension, 2016, 18, 477-478.	1.0	7
180	Blood pressure response to treatment of obese vs nonâ€obese adults with sleep apnea. Journal of Clinical Hypertension, 2019, 21, 1580-1590.	1.0	7

#	Article	IF	CITATIONS
181	Large Artery Stiffness: A Companion to the 2015 AHA Science Statement on Arterial Stiffness. Pulse, 2021, 9, 1-10.	0.9	7
182	Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1015-1024.	2.2	7
183	Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Journal of Clinical Hypertension, 2022, 24, 339-349.	1.0	7
184	Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. Journal of Clinical Hypertension, 2011, 13, 889-897.	1.0	6
185	Lifestyle Modification in Blood Pressure Study II (LIMBS): Study protocol of a randomized controlled trial assessing the efficacy of a 24week structured yoga program versus lifestyle modification on blood pressure reduction. Contemporary Clinical Trials, 2013, 36, 32-40.	0.8	6
186	Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury. Evidence-Based Medicine, 2013, 18, 232-233.	0.6	6
187	Blood Pressure Targets in CKD. Advances in Chronic Kidney Disease, 2015, 22, 96-101.	0.6	6
188	"Translational―medicine: transforming SPRINT findings into clinical practice. Journal of the American Society of Hypertension, 2016, 10, 382-386.	2.3	6
189	Future use of the European Society of Hypertension International Protocol for validation of automated sphygmomanometers. Blood Pressure Monitoring, 2019, 24, 161-162.	0.4	6
190	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. BMC Nephrology, 2021, 22, 69.	0.8	6
191	Ambulatory Blood Pressure Monitoring and Hypertensive Target Organ Damage. American Journal of the Medical Sciences, 1996, 312, 221-224.	0.4	6
192	Attending Rounds. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2301-2306.	2.2	4
193	Investigating the Effect of Glucose on Aortic Pulse Wave Velocity Using Pancreatic Clamping Methodology. Biological Research for Nursing, 2015, 17, 270-275.	1.0	4
194	Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles. Contemporary Clinical Trials Communications, 2016, 3, 70-73.	0.5	4
195	Blood pressure in patients with atrial fibrillation: part 2—treatment. Journal of Clinical Hypertension, 2017, 19, 212-214.	1.0	4
196	<scp>Blood pressure</scp> readings using public kiosks or smart phone apps: Caveat emptor (for) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 5
197	Approach to the Young Patient with New-Onset Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 929-932.	2.2	4

¹⁹⁸Systolic blood pressure as a potential target of sigmaâ€l receptor agonist therapy. Journal of Clinical
Hypertension, 2018, 20, 416-417.1.04

#	Article	IF	CITATIONS
199	Imaging strategies for safety surveillance after renal artery denervation. Clinical Research in Cardiology, 2021, 110, 609-619.	1.5	4
200	Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension, 2021, 77, 2023-2033.	1.3	4
201	The Association Between Socioeconomic Factors and Incident Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort (CRIC). Annals of Vascular Surgery, 2022, 80, 196-205.	0.4	4
202	Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort. Digital Health, 2022, 8, 205520762211079.	0.9	4
203	Hypertension in renal failure. Disease-a-Month, 1998, 44, 243-253.	0.4	3
204	Differential effect of insulin on saturated and unsaturated fatty acids. Metabolism: Clinical and Experimental, 2002, 51, 779-782.	1.5	3
205	Renal denervation for the treatment of hypertension: Making a new start, getting it right. Catheterization and Cardiovascular Interventions, 2015, 86, 855-863.	0.7	3
206	Arterial stiffness and reference values. Revista Espanola De Cardiologia (English Ed), 2020, 73, 11-13.	0.4	3
207	Health-Related Quality of Life, Depressive Symptoms, and Kidney Transplant Access in Advanced CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Medicine, 2020, 2, 600-609.e1.	1.0	3
208	Changes in sleepiness and 24-h blood pressure following 4 months of CPAP treatment are not mediated by ICAM-1. Sleep and Breathing, 2021, 25, 1495-1502.	0.9	3
209	Ambulatory and Home Blood Pressure Monitoring in Hemodialysis Patients: A Mixed-Methods Study Evaluating Comparability and Tolerability of Blood Pressure Monitoring. Kidney Medicine, 2021, 3, 457-460.	1.0	3
210	Residual Risk. Journal of Clinical Hypertension, 2003, 5, 362-363.	1.0	2
211	Sitting on the Evidence: What Is the Proper Patient Position for the Office Measurement of Blood Pressure?. Journal of Clinical Hypertension, 2005, 7, 365-366.	1.0	2
212	The Associations between Peripheral Artery Disease and Physical Outcome Measures in Men and Women with Chronic Kidney Disease. Annals of Vascular Surgery, 2016, 35, 111-120.	0.4	2
213	The Value in an Ambulatory Blood-Pressure Registry. New England Journal of Medicine, 2018, 378, 1555-1556.	13.9	2
214	Therapeutic Options to Improve Cardiovascular Outcomes with Long-Term Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 511-513.	2.2	2
215	Evaluation of Hypertension. Nephrology Self-assessment Program: NephSAP, 2020, 19, 8-19.	3.0	2
216	Socioeconomic status impacts blood pressure response to positive airway pressure treatment. Journal of Clinical Sleep Medicine, 2022, 18, 1287-1295.	1.4	2

#	Article	IF	CITATIONS
217	Nonâ€Aspirin Nonsteroidal Antiâ€Inflammatory Drugs. Journal of Clinical Hypertension, 2002, 4, 436-440.	1.0	1
218	Am I More Likely to Develop Diabetes If I Have High Blood Pressure?. Journal of Clinical Hypertension, 2003, 5, 175-176.	1.0	1
219	"ROADMAP―Controversies. Journal of Clinical Hypertension, 2011, 13, 628-628.	1.0	1
220	Novel Uses of Office-Based Measures of Arterial Compliance. Methodist DeBakey Cardiovascular Journal, 2015, 11, 219-222.	0.5	1
221	Variants in genes belonging to the fibroblast growth factor family are associated with lower extremity amputation in nonâ€Hispanic whites: Findings from the chronic renal insufficiency cohort study. Wound Repair and Regeneration, 2016, 24, 705-711.	1.5	1
222	Response to Budoff and Steigerwalt. Journal of the American Society of Hypertension, 2016, 10, 470-471.	2.3	1
223	Medication Nonâ€Adherence: A Bigger Problem Than Physicians Assume. Journal of Clinical Hypertension, 2016, 18, 949-950.	1.0	1
224	Blood pressure goals, variability and SGLT2 blockade in CKD. Nature Reviews Nephrology, 2017, 13, 75-76.	4.1	1
225	Pathophysiology of Hypertension in ChronicÂKidney Disease. , 2020, , 313-322.		1
226	Refractory or Resistant Hypertension. Journal of Clinical Hypertension, 2002, 4, 61-61.	1.0	0
227	Acupuncture in Hypertension. Journal of Clinical Hypertension, 2002, 4, 229-229.	1.0	Ο
228	"+1―Proteinuria in the Nondiabetic Hypertensive. Journal of Clinical Hypertension, 2002, 4, 309-309.	1.0	0
229	The Forgetful Hypertensive Patient. Journal of Clinical Hypertension, 2003, 5, 89-89.	1.0	0
230	Can I Stop Taking This Blood Pressure Medicine?. Journal of Clinical Hypertension, 2003, 5, 234-234.	1.0	0
231	Aldosterone Redux. Journal of Clinical Hypertension, 2003, 5, 300-300.	1.0	0
232	Finding vs Controlling Hypertension—Mind the Gap!. Journal of Clinical Hypertension, 2007, 9, 974-974.	1.0	0
233	On the Waterfront. Advances in Chronic Kidney Disease, 2011, 18, 3-5.	0.6	0
234	Interventional management in hypertension. Current Opinion in Nephrology and Hypertension, 2014, 23, 444-448.	1.0	0

#	Article	IF	CITATIONS
235	An Update on Treatment Options for Drug Resistant Hypertension. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	0
236	To Restrict or Not to Restrict? The Enigma of Sodium Intake and Mortality. American Journal of Kidney Diseases, 2015, 65, 9-11.	2.1	0
237	What Is Happening in the Area of Deviceâ€Based Blood Pressure Treatment?. Journal of Clinical Hypertension, 2016, 18, 247-247.	1.0	0
238	2003 Mixed meal effects of neprilysin inhibition. Journal of Clinical and Translational Science, 2018, 2, 44-44.	0.3	0
239	FP385PREDICTIVE MODELS FOR THE DEVELOPMENT OF PERIPHERAL ARTERY DISEASE AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
240	Revisiting Renal Denervation. Mayo Clinic Proceedings, 2019, 94, 1665-1667.	1.4	0
241	Treating Hypertension Using Renal Artery Denervation: Problems and Progress. Advances in Chronic Kidney Disease, 2019, 26, 117-121.	0.6	0
242	Norman M. Kaplan. Hypertension, 2020, 76, 291-293.	1.3	0
243	Hypertensive Emergencies. , 2007, , 666-677.		0
244	Blood Pressure: Definition, Diagnosis, and Management. , 2016, , 3-15.		0
245	Is There Any Role for Device Therapies in Resistant Hypertension? PRO. Kidney360, 2020, 1, 6-8.	0.9	0
246	Arterial stiffness and pulsatile hemodynamics in renal disease. , 2022, , 637-647.		0